title: Prostate-specific antigen after cryosurgical ablation of the prostate. Defining the appropriate response.
abstract: The ability of prostate-specific antigen (PSA) to predict long-term cure after cryotherapy for localized prostate cancer is not known because experience with this treatment modality is limited; however, it appears that a PSA value of 0.5 ng/mL or less at 6 months or longer after cryotherapy is associated with a high probability of a negative post-treatment biopsy (greater than 95%). An undetectable PSA (less than 0.1 ng/mL) 3 months after the procedure is associated with a likelihood of a negative biopsy at 6 months and low, stable PSA levels up to 2 years.
authors.affiliation: Department of Urology, University of California, School of Medicine, San Francisco, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Connolly
authors.forename: K
authors.initials: K
authors.lastname: Shinohara
authors.forename: J C
authors.initials: JC
authors.lastname: Presti
authors.forename: P R
authors.initials: PR
authors.lastname: Carroll
mesh_terms: D001706:Biopsy; D003452:Cryosurgery; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000601:surgery*; D012680:Sensitivity and Specificity
chemical_list: D017430:Prostate-Specific Antigen